Feed MESO
ME

Mesoblast Limited

MESO · NASDAQ

$15.13 +1.44% (+$0.22)
1M -9.07%
Market Cap $1.93B
P/E Ratio -
Div. Yield -
ROE 9.98%
Piotroski F-Score Moderate
4/9
Valuation
30 /100
Expensive
P/B 3.39x
P/S 15.97x
EV/EBITDA N/A
Growth
88 /100
Growing
Book val. growth 4.24%
Rev. growth 152.52%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 47.82%
Op. margin 42.64%
FCF margin 37.03%
Quality
2 /100
Poor
ROE 9.98%
ROA 7.47%
Asset turnover 0.16x
Debt
69 /100
Low
Current ratio 2.43x
Int. coverage -2.15x
Debt/Equity 0.22x
Stability
50 /100
Moderate
Rev. volatility 317.03%
EPS volatility 22.60%
Profitable years 0

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre MESO
Online

Despre companie

Mesoblast Limited is an Australian biopharmaceutical company specializing in the development and commercialization of regenerative therapeutic products for the treatment of various diseases. The company focuses on using cell therapy and biological drugs to regenerate and repair tissues. Their main product portfolio includes therapeutic products for the treatment of bone and joint diseases, heart diseases, skin diseases, and autoimmune disorders. Mesoblast boasts a range of clinical studies and research projects exploring the potential of their therapeutic products in various indications. The company is known for its expertise in the field of cell therapy and regenerative medicine. Mesoblast Limited shares could be an interesting choice for investors looking for opportunities in biotechnology and regenerative medicine treatment.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Silviu Itescu

Employees

108

Headquarters

Melbourne

Evenimente viitoare

04 MAR.

Earnings

Upcoming earnings report

164d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.